Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial

McCormack, Sheena; Dunn, David; Desai, Monica; Dolling, David; Gafos, Mitzy; Gilson, Richard; Sullivan, Ann; Clarke, Amanda; Reeves, Iain; Schembri, Gabriel; Mackie, Nicola; Bowman, Christine; Lacey, Charles; Apea, Vanessa; Brady, Michael; Fox, Julie; Taylor, Stephen; Antonucci, Simone; Khoo, Saye; F. Rooney, James; Nardone, Anthony; Fisher, Martin; McOwan, Alan; Phillips, Andrew; M Johnson, Anne; Gazzard, Brian; N Gill, O

doi:10.1016/s0140-6736(15)00056-2

Public

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial

Published in The Lancet • Sep 11, 2015

Authors:

Sheena McCormack

David Dunn

Monica Desai

Abstract

BACKGROUND: Randomised placebo-controlled trials have shown that daily oral pre-exposure prophylaxis (PrEP) with tenofovir-emtricitabine reduces the risk of HIV infection. However, this benefit could be counteracted by risk compensation in users of PrEP. We did the PROUD study to assess this effect....

Subject

Medicine

Emtricitabine

Pre-exposure prophylaxis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!